San Diego, October 14, 2026 / PRNewswire / -- Illumina , Inc. (Nasdaq ticker: ILMN) On Tuesday, the company released Illumina BioInsight Platform, its first unified software environment designed to help researchers transform complex genomic and multi-omics data into meaningful biological evidence.
Illumina indicates that the platform integrates the company's analytical applications, the specially crafted AI innovations, and selected data resources into a single environment, providing greater flexibility and accessibility. At the same time, it reduces the need to assemble and manage individual informatics tools as research questions continue to evolve.
Illumina BioInsight, Senior Vice President and General Manager, and Rami Mehio stated: " BioInsight is built on the outstanding foundation established by Illumina over more than a decade in data, software, and AI innovation for the industry. Now, BioInsight is accelerating our pace of innovation, and with the help of BioInsight Platform, we bring a complete range of products in software, AI, and data to our customers through a single, simple entry point. Most importantly, we have just begun. Customers using BioInsight Platform will also receive new features in the future that will help them drive the next wave of biological insights in the industry."
Next-generation sequencing has transformed researchers' ability to generate genomic and multi-omics data. However, the scale and complexity of these datasets also present new challenges: how to efficiently convert this data into insights. The BioInsight business unit of Illumina was established a year ago with the aim of addressing this gap. AI has become an important technology for rapidly interpreting biological variations and prioritizing the identification of meaningful signals. BioInsight Platform enables researchers to utilize the innovative combinations of Illumina genomics, including the recently released SpliceAI2 model for rare disease research.
With the launch of BioInsight Platform, this business department has now integrated the data from Illumina, AI, and software products through a single sign-on approach. The BioInsight business also includes projects such as Billion Cell Atlas, which connects proprietary data with leading biopharmaceutical partners to help advance the next generation of drug discovery and development.
Specially created AI to assist researchers in large-scale interpretation of biological variations
BioInsight AI Lab is a research department of BioInsight. It utilizes multi-omics data and AI to predict variant effects, rank the priority of these effects, and train biological foundation models. These models, specifically designed for genomics, known as AI, assist researchers in identifying, sorting, and interpreting biologically relevant signals within increasingly complex datasets, thereby enabling a deeper exploration of disease biology and genetic variations.
DRAGEN v4.6 Expand the scope of use for high-performance secondary analysis
BioInsight Platform also includes the newly released DRAGEN version, DRAGEN, and v4.6, which expand the scenarios and methods in which researchers can use this award-winning secondary analysis software. Data residency requirements, infrastructure limitations, and operational needs can all affect where and how genomics and multi-omics analyses are conducted. New deployment options, including DRAGEN, software, and mode, enable institutions to run DRAGEN in supported cloud environments and standard CPU environments. DRAGEN and v4.6 can provide consistent analysis results in supported computing environments, allowing institutions to run DRAGEN in the environment that best suits their needs, while maintaining confidence in the results.
Researchers are already utilizing DRAGEN, software, and mode to support large-scale genomic discovery projects. According to Illumina, in collaboration with Global Parkinson's Genetics Program ( GP2 ), DRAGEN is supporting approximately 170 active research projects that focus on the genetic basis of Parkinson's disease. GP2 is a resource project of Aligning Science Across Parkinson's ( ASAP ) and collaborates with The Michael J. The faster processing speed, as well as the ability to run analyses efficiently and consistently in a public cloud environment, are helping GP2 to accelerate and share its large-scale genomic cohort studies.
The Andrew Singleton of GP2 indicates that: " GP2 is promoting research on a global scale to explore genetic risks and expand our understanding of Parkinson's disease. Advances in software are crucial for helping our researchers understand genetic data in a consistent, comprehensive, and scalable analytical environment. The combination of speed and scalability allows us to focus more on scientific issues rather than operational bottlenecks."
Selected biological data helps researchers place their discoveries in context for better understanding.
BioInsight Platform provides expert-curated datasets covering oncology, rare diseases, population health, and multi-omics research. BioInsight Data transforms public and proprietary datasets into a unified, annotated, and reusable scientific catalog, complemented by AI models designed specifically for genomics and multi-omics applications. These continuously updated datasets enable researchers to contextualize findings across studies, propose new hypotheses, and accelerate biological discoveries.
BioInsight Platform integrates the continuously expanding portfolio of informatics applications from Illumina, which includes DRAGEN, Emedgene, Connected Multiomics, BioInsight Platform Core, BaseSpace, and BioInsight Data. The pay-as-you-go BioInsight Credits model has replaced the traditional annual subscription, allowing researchers to adopt the functions that best suit their work needs while maintaining flexibility to evaluate new technologies as scientific requirements evolve.
BioInsight is dedicated to the data, software, informatics, and AI services of Illumina. It assists researchers, medical institutions, and biopharmaceutical companies in transforming genomics and multi-omics data into biological insights. BioInsight enables clients to accelerate the discovery, identification, and validation of drug targets, deepen their understanding of disease biology, and advance precision medicine. The continuously expanding product portfolio also includes groundbreaking BioInsight AI Lab, as well as resources such as Billion Cell Atlas, which help biopharmaceutical partners link genetic signals with cellular mechanisms and biological functions.
Illumina indicates that BioInsight Platform (booth number 701) will be displayed at the annual meeting of the American Society of Human Genetics ( ASHG ) to be held next week in Montreal. Researchers can register for a free trial of BioInsight Platform here.
About Illumina
Illumina improves human health by unleashing the power of the genome. Focusing on innovation, the company has become a global leader in DNA sequencing and chip-based technologies, serving customers in research, clinical, and application markets. Its products are used in life sciences, oncology, reproductive health, agriculture, and other emerging fields. For more information, visit illumina.com, and follow the company on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investor Contact: Illumina Investor Relations 858-291-6421 [ email protected ]
Media Contact: Christine Douglass [ email protected ]
